Published in Int J Mol Sci on December 14, 2016
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med (2010) 13.70
Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care (2012) 7.83
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem (2002) 6.96
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology (2011) 6.33
Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell (1999) 5.01
Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med (2004) 3.59
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care (2010) 3.29
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J (2004) 3.12
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem (2007) 3.07
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol (2014) 2.80
Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med (2004) 2.73
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol (2009) 2.47
The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol (2004) 2.05
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet (2016) 1.93
The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology (2009) 1.87
Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res (2008) 1.85
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65
Fingolimod-associated macular edema: incidence, detection, and management. Neurology (2012) 1.58
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol (2013) 1.47
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant (2006) 1.45
FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol (2008) 1.45
Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J (2014) 1.27
Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol (2010) 1.27
Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal (2007) 1.24
FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation (2007) 1.21
Balance of S1P1 and S1P2 signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature. Am J Physiol Heart Circ Physiol (2008) 1.20
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) (2015) 1.14
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology (2013) 1.12
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology (2015) 1.12
A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler (2012) 1.10
Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci (2012) 1.09
Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch Ophthalmol (2008) 1.09
Does fingolimod in multiple sclerosis patients cause macular edema? J Neurol (2012) 1.06
Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol (2013) 1.02
FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant (2011) 0.99
Drug-induced macular edema. Drugs (2013) 0.99
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol (2014) 0.98
FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl. Eur Respir J (2010) 0.97
Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol (2009) 0.96
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis. Case Rep Med (2012) 0.95
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation (2004) 0.95
Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation (2006) 0.93
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry (2015) 0.90
FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer (2014) 0.89
Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use. JAMA Ophthalmol (2013) 0.89
Management of fingolimod-associated macular edema. JAMA Ophthalmol (2013) 0.89
FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am J Transplant (2006) 0.88
Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study. Adv Ther (2015) 0.86
FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease. J Mol Histol (2013) 0.86
FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke. PLoS One (2013) 0.86
Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use. Mult Scler (2014) 0.86
Continuing fingolimod after development of macular edema: A case report. Neurol Neuroimmunol Neuroinflamm (2014) 0.85
FTY720 protects cardiac microvessels of diabetes: a critical role of S1P1/3 in diabetic heart disease. PLoS One (2012) 0.84
Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization. Br J Pharmacol (2014) 0.83
FTY720 attenuates paraquat-induced lung injury in mice. Int Immunopharmacol (2014) 0.81
Sphingosine signalling regulates decidual NK cell angiogenic phenotype and trophoblast migration. Hum Reprod (2013) 0.81
Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. PLoS One (2015) 0.81
Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait. CNS Drugs (2014) 0.81
Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis. Int J Rheum Dis (2012) 0.80
Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Mult Scler (2013) 0.79
The effectiveness of fingolimod in a Portuguese real-world population. Mult Scler Relat Disord (2016) 0.79
Microaneurysm count as a predictor of long-term progression in diabetic retinopathy in young patients with type 1 diabetes: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987). Graefes Arch Clin Exp Ophthalmol (2014) 0.79
Altered expression of signaling genes in Jurkat cells upon FTY720 induced apoptosis. Int J Mol Sci (2010) 0.79
Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. Mult Scler Relat Disord (2015) 0.78
Severe early bilateral macular edema following fingolimod therapy. Mult Scler Relat Disord (2013) 0.78
Higher age at onset of type 1 diabetes increases risk of macular oedema. Acta Ophthalmol (2012) 0.77
Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report. BMC Ophthalmol (2015) 0.77
Famous. Surv Ophthalmol (2015) 0.76
FTY720 Attenuates Retinal Inflammation and Protects Blood-Retinal Barrier in Diabetic Rats. Invest Ophthalmol Vis Sci (2016) 0.76